glp-1 receptor agonist nephrolithiasis Frontiers Trends in the Development of

Traditionally, both single and combination FDA-approved drugs for obesity have shown moderate, but clinically-important, weight losses (mean weight loss of 3%9% greater than placebo at ~1 year of therapy) (4) (Figure 1)

doi: 10.1097/JIM.0000000000000129 [DOI] [PubMed] [Google Scholar] 156

Brito, J

Table 1 Characteristics of available GLP-1 receptor agonists

This has led to doubts about the importance of an incretin role for pharmacological GLP-1 administration, because incretin hormones should lead to a net increase in post-nutrient insulin secretory responses [810]

For example, Morgan Stanley 4 estimates the current U.S